V600E - Wikipedia
网页V600E is a mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600. [1][2] It is a driver mutation in a proportion of certain diagnoses, including melanoma, [3][4] hairy cell leukemia, [5][6] papillary thyroid carcinoma, [7][8] colorectal cancer, [9] non-small-cell lung cancer, [10][11] Langerhans ...
BRAFV600E-mutant metastatic NSCLC: disease overview and …
网页2024年4月16日 · The BRAF V600E mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to...
网页BRAF V600E突变基因已成为甲状腺乳头状癌已知的重要驱动基因,在疾病诊断、病情评估、治疗策略、预后判断等方面起重要作用。 本文对BRAF V600E在以上四个方面中的应用进展进行综述。 关键词. BRAF V600E,甲状腺乳头状癌,综述. Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma. Yanze Liu1*, Jiaqi Liu2, Liang Li2#
a tumour-agnostic drug target with lineage-specific dependencies
网页2024年1月26日 · The FDA-approved BRAF inhibitors vemurafenib, dabrafenib and encorafenib selectively inhibit activated BRAF V600E/K/R/D monomers (class I BRAF mutants) in cancer cells, which underlies their...
BRAF V600E Mutation Across Multiple Tumor Types: Correlation …
网页An activating missense mutation in codon 600 of exon 15 (V600E) of BRAF gene has been identified in multiple neoplasms including melanoma, colorectal carcinoma, papillary thyroid carcinoma, hairy cell leukemia, and Langerhans cell histiocytosis. Patients with BRAF V600E-mutated melanoma respond to FDA-approved BRAF inhibitors.
The Evolutionary Landscape of Treatment for BRAFV600E …
网页2021年1月4日 · The BRAFV600E mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months.
BRAFV600E: Implications for Carcinogenesis and Molecular …
网页2011年3月8日 · BRAF V600E is an attractive target for molecular therapy. Inhibitors targeted against BRAF and its primary downstream target MEK are producing interesting results in early-phase clinical trials. In this article, the molecular aspects of BRAF V600E and the consequences of this activating mutation are reviewed.
Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: …
网页2023年4月14日 · Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E...
Implications of BRAF V600E mutation in gliomas: Molecular ...
网页2023年1月4日 · Despite the relatively low incidence of BRAF V600E mutations in high grade gliomas, mounting evidence has suggested that BRAF targeted therapy represents a promising treatment option for adults with BRAF mutated high grade gliomas or GBM.
BRAF V600E - My Cancer Genome
网页BRAF V600E is an inclusion criterion in 47 clinical trials for melanoma, of which 29 are open and 18 are closed. Of the trials that contain BRAF V600E and melanoma as inclusion criteria, 17 are phase 1 (9 open), 12 are phase 1/phase 2 (9 open), 16 are phase 2 (10 open), and 2 are phase 3 (1 open) [.
- 某些结果已被删除